Is there strong sentiment enough to push itrm price up tomorrow

The sentiment around Iterum Therapeutics (ITRM) is positive, which could potentially push the stock price up tomorrow. Here's an analysis based on the latest information:

1. Analyst Ratings and Price Targets:
   • ITRM has a "Strong Buy" consensus rating, indicating a positive outlook from analysts.
   • The average price target is $5.33, suggesting a potential upside from the current price.
2. Recent Stock Performance:
   • ITRM's stock price increased by 1.7% on a recent trading day, showing positive momentum.
   • The stock has experienced fluctuations, with highs and lows ranging from $2.50 to $0.62 over the past year.
3. Patent Developments:
   • Iterum Therapeutics has strengthened its patent estate for oral sulopenem, which could be a positive factor for the company's future revenue streams.
4. FDA Advisory Committee Meeting:
   • The FDA's Antimicrobial Drugs Advisory Committee (AMDAC) discussed Iterum's New Drug Application (NDA) for oral sulopenem, which could have implications for the drug's future approval.
   • The FDA has not yet made a decision on the application, but the fact that it held the meeting indicates that the drug is under consideration for approval.
5. Market Conditions:
   • The broader market conditions, including investor sentiment towards the pharmaceutical sector and the overall stock market, will also influence ITRM's price movement.

In conclusion, the positive analyst ratings, potential for drug approval, and recent stock performance indicate a bullish sentiment for ITRM. However, investors should monitor the FDA's decision on the sulopenem application and broader market conditions. Investors should exercise caution and consider these factors when making investment decisions.